BioAge Labs doses first patient in BGE-102 phase 1 trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Reinforcing commitment to ethical and sustainable growth
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
cSCC is one of the most common cancers in the U.S. and globally
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The submission is supported by results from the Phase 3b APEX study
Subscribe To Our Newsletter & Stay Updated